How many insider trades does FilingIQ track for NKTX?

FilingIQ tracks 175 Form 4 insider transactions for NKTX (Nkarta, Inc.), covering filings from Jul 14, 2020 onwards. 9 of those were filed in the last 90 days.

Are NKTX insiders net buyers or net sellers?

Across the full Form 4 history for NKTX, 11 transactions (6%) were open-market purchases and 69 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NKTX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NKTX in?

Nkarta, Inc. (NKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $146.86M.

NKTX insider trading

NasdaqGS Healthcare

Nkarta, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

175

Last 90 days

Buys / sells

6% / 39%

Market cap

$146.86M

About Nkarta, Inc.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Company website: www.nkartatx.com

NKTX insider activity at a glance

FilingIQ has scored 175 insider transactions for NKTX since Jul 14, 2020. The most recent filing in our index is dated Jun 18, 2026.

Across the full history, 11 open-market purchases and 69 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NKTX insider trades is 56.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live NKTX trades on FilingIQ Raw filings on SEC EDGAR

Latest NKTX Form 4 filings

HASTINGS PAUL J Chief Executive Officer

S Jan 15, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,165

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

KYMR 178

Kymera Therapeutics, Inc.

First Tracks Biotherapeutics, Inc.

13F funds holding NKTX

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

$72.71M · 1.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for NKTX?: FilingIQ tracks 175 Form 4 insider transactions for NKTX (Nkarta, Inc.), covering filings from Jul 14, 2020 onwards. 9 of those were filed in the last 90 days.
Are NKTX insiders net buyers or net sellers?: Across the full Form 4 history for NKTX, 11 transactions (6%) were open-market purchases and 69 (39%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NKTX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NKTX in?: Nkarta, Inc. (NKTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $146.86M.

Methodology & sources

Every NKTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.